Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

21 Dec 2015 18:22

RNS Number : 8050J
GW Pharmaceuticals PLC
21 December 2015
 



GW Pharmaceuticals PLC Director/PDMR Shareholding

21 December 2015

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

 

Cambridge, UK, 21 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has been notified of the following series of transactions in the shares of GW Pharmaceuticals plc.

 

On 18 December 2015 the Company was notified that on 17 December 2015 Mr Cabot Brown, a non-executive Director of the Company, purchased 600 American Depository Shares, or ADS (equivalent to 7,200 ordinary 0.1 pence shares) of GW Pharmaceuticals plc, at a price of $68.864 per ADS (equivalent to 384 pence per share).

 

Following this notification Mr Brown's interest in the shares of GW Pharmaceuticals plc is 7,200 ordinary 0.1 pence shares (equivalent to 600 ADSs), representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Mr. Chris Tovey, a Director and Chief Operating Officer of the Company, exercised options to acquire 24,000 ordinary 0.1 pence shares (equivalent to 2,000 ADSs) of GW Pharmaceuticals plc. These options had an exercise price of 0.1 pence per share. The Company has been notified that on 18 December 2015 these shares, representing less than 0.1% of shares in issue, were converted to 2,000 ADSs and immediately sold at an average price of $67.6275 per ADS (equivalent to 378 pence per share).

 

Following these transactions, Mr. Tovey's beneficial interested in the Company's ordinary 0.1 pence shares is 2,500 shares, representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Dr. Geoffrey Guy, a Director and Chairman of the Company, exercised options to acquire 1,369,848 ordinary 0.1 pence shares (equivalent to 114,154 ADSs) of GW Pharmaceuticals plc. These options had a weighted average exercise price of 41 pence per ordinary 0.1 pence share. The Company has been notified that (1) on 18 December 2015, 1,065,936 of these shares were converted to 88,828 ADSs and immediately sold at an average price of $67.50 per ADS (equivalent to 377 pence per share) and (2) earlier today a further 10,309 ADSs (equivalent to 123,708 ordinary 0.1 pence shares) were sold at an average price of $67.32 per ADS (equivalent to 376 pence per share). Exercise of these options results in an immediate UK income tax liability for Dr. Guy necessitating the immediate sale of a significant number of the resulting shares. In addition, we have been notified that earlier today 6,000 ordinary 0.1 pence shares held by Dr Guy's personal pension scheme were sold at an average price of 366 pence per share.

 

Following these transactions, Dr. Guy's notifiable interest in the ordinary 0.1 pence shares of the Company has increased by 174,204 shares to 14,297,852 shares, representing 5.4% of the Company's current issued share capital.

 

The total number of shares outstanding in the Company is 262,574,021 ordinary 0.1 pence shares.

 

For further information, please contact:

 

GW Pharmaceuticals plc

Adam George, Company Secretary

+44 (0)1980 557 000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFTFLLLFIE
Date   Source Headline
1st Dec 201611:15 amRNSAmerican Society of Epilepsy Annual Meeting
30th Nov 20161:00 pmRNSNotice of Q4 and year-end results
24th Nov 20167:30 amRNSHolding(s) in Company
22nd Nov 20161:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
18th Nov 20169:31 amRNSHolding(s) in Company
11th Nov 20165:01 pmRNSHolding(s) in Company
10th Nov 201611:03 amRNSDirector/PDMR Shareholding
3rd Nov 20161:58 pmRNSDirector/PDMR Shareholding
3rd Nov 20167:50 amRNSHolding(s) in Company
3rd Nov 20167:47 amRNSHolding(s) in Company
2nd Nov 20165:05 pmRNSDirector/PDMR Shareholding
1st Nov 20169:58 amRNSDirector/PDMR Shareholding
31st Oct 20163:29 pmRNSHolding(s) in Company
31st Oct 20162:59 pmRNSTotal Voting Rights
31st Oct 20168:25 amRNSHolding(s) in Company
28th Oct 20164:58 pmRNSDirector Stock Trading Plan
28th Oct 20164:57 pmRNSDirector/PDMR Shareholding
26th Oct 20165:26 pmRNSDirector/PDMR Shareholding
25th Oct 20165:43 pmRNSDirector/PDMR Shareholding
21st Oct 20164:37 pmRNSPosting of Shareholder Circular
20th Oct 20163:30 pmRNSHolding(s) in Company
19th Oct 20167:00 amRNSIntention to Trade Exclusively on NASDAQ
7th Oct 201610:22 amRNSDirector Stock Trading Plan - Replacement
6th Oct 20166:01 pmRNSDirector Stock Trading Plan
30th Sep 20161:48 pmRNSTotal Voting Rights
26th Sep 201611:57 amRNSSecond Positive Phase 3 Trial for Epidiolex in LGS
14th Sep 20165:27 pmRNSDirector/PDMR Shareholding
7th Sep 201612:00 pmRNSPresenting at Morgan Stanley Healthcare Conference
31st Aug 201612:18 pmRNSTotal Issued Share Capital
17th Aug 20168:56 amRNSBlock listing Interim Review
9th Aug 201612:00 pmRNS3rd Quarter Results
9th Aug 201612:00 pmRNSNotification of Future Change to Board
2nd Aug 201612:00 pmRNSNotice of Results
29th Jul 201610:58 amRNSTotal Voting Rights
25th Jul 20167:57 amRNSHolding(s) in Company
21st Jul 201610:08 amRNSHolding(s) in Company
21st Jul 201610:04 amRNSHolding(s) in Company
19th Jul 20169:37 amRNSTotal Voting Rights
18th Jul 20164:15 pmRNSClosing of U.S. Public Offering Raising $289.8m
13th Jul 20167:00 amRNSUS Public Offering of ADSs Raising $252.0 Million
13th Jul 20167:00 amRNSProposed Public Offering of ADSs
1st Jul 20163:14 pmRNSHolding(s) in Company
1st Jul 20168:03 amRNSHolding(s) in Company
30th Jun 20163:22 pmRNSTotal Voting Rights
28th Jun 201612:14 pmRNSHolding(s) in Company
27th Jun 201612:07 pmRNSSecond Price Monitoring Extn
27th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201612:00 pmRNSPositive Phase 3 Pivotal Trial Results
27th Jun 201610:00 amRNSHolding(s) in Company
23rd Jun 20167:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.